|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
2929 Arch St, 3rd Floor, Philadelphia, Pennsylvania 19104, US
|
|
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer. For additional information on BriaCell, please visit our website: http://briacell.com/
|
BriaCell Therapeutics Corp. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used BriaCell Therapeutics Corp. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact BriaCell Therapeutics Corp. customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.